Hepion Pharmaceuticals

HEPAPhase 2

Morristown, United Stateshepionpharma.com

Hepion Pharmaceuticals is on a mission to redefine the early detection of hepatocellular carcinoma by delivering non-invasive, clinically grounded liquid biopsy solutions for patients at highest risk, particularly those with cirrhosis. The company's strategy involves advancing complementary biomarker platforms—methylated DNA (mSEPT9) and next-generation circulating tumor RNA (ctRNA)—with the goal of detecting HCC at its earliest, most treatable stages. Hepion is pursuing a disciplined path to value creation through CLIA deployment, FDA approval, and strategic partnerships, with the long-term vision of extending its diagnostic capabilities to other solid tumors where early detection remains a critical unmet need.

Market Cap

$697K

Focus

Small Molecules

HEPA · Stock Price

USD 0.061259.94 (-100.00%)

Historical price data

AI Company Overview

Technology Platform

Hepion utilizes a dual liquid biopsy platform: a clinically validated methylated DNA (SEPT9) biomarker test for near-term HCC detection, and a circulating tumor RNA (ctRNA) biomarker assay with potential for multi-cancer early detection and surveillance.

Pipeline Snapshot

5 drugs in pipeline

Drug	Indication	Stage
rencofilstat, 75 mg + rencofilstat, 150mg + rencofilstat, 225 mg	NASH With Fibrosis	Phase 2
CRV431 75mg + Placebo (1 softgel) + CRV431 225mg + Placebo (3 softgels)	NASH - Nonalcoholic Steatohepatitis	Phase 2
Rencofilstat + Placebo	Nonalcoholic Steatohepatitis (NASH)	Phase 2
CRV431 + Placebo + TDF	Hepatitis B	Phase 1
[14C]-rencofilstat 225mg	NASH With Fibrosis	Phase 1

Opportunities

Hepion's primary growth opportunity is capturing a significant share of the global HCC surveillance market by offering a superior blood-based test.

Long-term, the ctRNA platform provides a potential pathway into the vast multi-cancer early detection (MCED) market.

Strategic partnerships with pharma, labs, or healthcare systems could accelerate commercialization and provide non-dilutive funding.

Risk Factors

Key risks include failure to successfully launch the CLIA test or gain FDA approval, inability to demonstrate superior clinical utility versus standard care, intense competition from larger diagnostic companies, challenges in securing adequate funding as a pre-revenue micro-cap, and execution risks associated with the ongoing leadership transition.

Competitive Landscape

Hepion competes with large liquid biopsy players like Exact Sciences, Guardant Health, and GRAIL (Illumina), as well as the entrenched standard of care (ultrasound/AFP). Its differentiation lies in a focused, dual-platform strategy for the high-risk cirrhosis population, combining a near-term asset (mSEPT9) with a next-generation ctRNA platform for future expansion.